ReviewDrug design, development and therapy2026
Wise as a Serpent and Gentle as a Dove: Pharmacological Targeting of NRF2/KEAP1 Pathway from Treasure Trove of Mother Nature.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Discovery of NRF2 in 1994 was once assumed simplistic and classical but the following years witnessed phenomenal breakthroughs that led to a rapid increase in the components of complex molecular web. Emerging evidence has enabled us to develop a better understanding of the spatio-temporally placed molecular machinery both upstream and downstream to the NRF2 in different contexts and diseases. The exciting voyage to unravel the multifaceted roles of NRF2 in human diseases has catalyzed innovations in therapeutic approaches, inspiring the design of compounds for pharmacological modulation of NRF2 in disease prevention and intervention. In this review, we have set the spotlight on sketching a detailed landscape both upstream and downstream to the central signaling node of NRF2. Identification of the natural products having unique ability to pharmacologically target NRF2-associated networks. Later, we expand our discussion about ongoing and completed clinical trials related to multifaceted roles of NRF2 as an oncogene and a tumor suppressor. We argue that a holistic view of NRF2-driven upstream and downstream signaling is necessary for the identification of preventive or therapeutic opportunities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.